Answers are grounded in this paper and cite their sources.
Review highlights issues in monitoring and lack of antidotes in patients using direct oral anticoagulants.
Anticoagulant drugs have undergone drastic changes in recent decades. The introduction of direct oral anticoagulants into clinical practice has led to their widespread use for long-term oral anticoagulant therapy. There is less control over therapy, and medications are prescribed by doctors of many specialties. This monitoring system for patients receiving direct oral anticoagulants is suboptimal. And the lack of antidotes for apixaban and rivaroxaban exacerbate the problem.
No takes yet. Share an insight, caveat, or question.
Gitelson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: